Emergent BioSolutions (NYSE:EBS) Shares Down 3.9% - What's Next?

Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report)'s share price dropped 3.9% during mid-day trading on Tuesday . The stock traded as low as $10.78 and last traded at $10.75. Approximately 113,481 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 992,138 shares. The stock had previously closed at $11.19.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on EBS. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Friday, January 24th. Finally, Benchmark upped their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research report on Thursday, November 7th.

Emergent BioSolutions Trading Up 1.9 %

The firm has a market cap of $613.32 million, a PE ratio of -2.77 and a beta of 1.60. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The stock's fifty day simple moving average is $9.54 and its 200-day simple moving average is $9.33.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 EPS for the quarter, topping analysts' consensus estimates of $0.49 by $0.88. The company had revenue of $293.80 million during the quarter, compared to analysts' expectations of $328.72 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same quarter in the previous year, the firm posted ($1.44) EPS. On average, sell-side analysts forecast that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Institutional Trading of Emergent BioSolutions

Large investors have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. acquired a new position in Emergent BioSolutions in the third quarter valued at approximately $1,547,000. Oak Hill Advisors LP acquired a new position in shares of Emergent BioSolutions in the 3rd quarter valued at $9,296,000. Assenagon Asset Management S.A. boosted its holdings in Emergent BioSolutions by 74.5% during the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company's stock worth $6,192,000 after buying an additional 316,700 shares in the last quarter. Barclays PLC grew its position in Emergent BioSolutions by 361.6% during the third quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company's stock valued at $329,000 after buying an additional 30,792 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Emergent BioSolutions by 4.6% in the third quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company's stock valued at $4,861,000 after buying an additional 25,776 shares in the last quarter. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.